Clinical Trial Inspections To Be Shared By FDA And EMEA Under Pilot Program
An initiative by FDA and the European Medicines Agency to share duties related to oversight of clinical trials may also reduce the resource burden on sponsors
You may also be interested in...
FDA and its counterparts in the European Union and Australia have divided responsibilities for inspecting specific active pharmaceutical ingredient facilities in third-country locations in the next 18 months as part of a pilot to monitor more sites
The firms that obtained FDA/EMEA qualification of seven nephrotoxicity biomarkers for preclinical drug testing are midway through development of a protocol to test their efficacy in a clinical trial
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011